In the July issue, we published an article exploring the efforts to deal with the drug shortage issue. We asked our online reading community if they thought these regulatory and legislative actions would be effective.
- 38% said they thought the recent actions would help resolve the issue
- 62% indicated they were not confident that recent actions would be effective
Here’s a sample of the comments:
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for Velcade (bor tezomib) for Injection (Millennium: The Takeda Oncology Company) that updates the label to include additional longterm (median follow-up 60.1 months) overall survival (OS) data from the VISTA trial. The VISTA trial examined the use of bortezomib-based therapy in patients with previously untreated multiple myeloma (MM).
Patients may not understand the information medical care providers give them for a number of reasons, but significant among them is poor healthcare literacy, which is the ability to understand health information and to use that information to make good decisions about health and medical care. Unfortunately, about 33% of the adult population in the United States has limited healthcare literacy. Yet, the need for this proficiency is greater than ever because medical care has become progressively more complex. Let us take a look at healthcare literacy facts and figures:
An investigational alpha-pharmaceutical not only prevented skeletal-related events (SREs) in patients with prostate cancer with bone metastases in a phase 3 study presented at the 2011 European Multidisciplinary Cancer Congress, but it also improved overall survival.
Results 251 - 260 of 315